<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421447</url>
  </required_header>
  <id_info>
    <org_study_id>06-375</org_study_id>
    <nct_id>NCT00421447</nct_id>
  </id_info>
  <brief_title>Bone Geometry and Muscle Density Changes in Postmenopausal Women and Breast Cancer Patients Prescribed Anastrozole</brief_title>
  <official_title>Bone Geometry and Muscle Density Changes in Postmenopausal Women and Breast Cancer Patients Prescribed Anastrozole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine if trabecular or cortical volumetric bone&#xD;
      mineral density (vBMD) change over time in postmenopausal breast cancer patients who are&#xD;
      prescribed Anastrozole, as measured by pQCT at the proximal and distal radius and tibia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In bone, where estrogen is required to maintain density, there is indication of increased&#xD;
      turnover in patients prescribed Aromatase Inhibitors. However, there are no studies to date&#xD;
      that prospectively quantify the impact of Aromatase inhibitors on bone quality. Furthermore,&#xD;
      the actual effects and clinical significance of adjuvant chemotherapy and supportive&#xD;
      medications on bone quality in women with breast carcinoma is unknown. The current study&#xD;
      proposes to prospectively assess novel skeletal health outcomes, namely trabecular structure&#xD;
      (connectivity, hole size) and bone geometry (bone area, cortical thickness) among women with&#xD;
      breast cancer being treated with Anastrozole. Not only will the current study provide a&#xD;
      better understanding of the changes in bone quality and muscle mass after Anastrozole&#xD;
      treatment, it will provide important information about the development of secondary skeletal&#xD;
      complications in this population. Therefore, the potential to collect data prospectively from&#xD;
      a cohort of individuals with breast cancer being treated with Anastrozole represents an&#xD;
      important step to advance knowledge in this area. Also, by examining bone quality and&#xD;
      secondary complications in a diverse cohort of patients who vary with respect to radiation&#xD;
      therapy, chemotherapy and additional medications, we can begin to identify patterns of&#xD;
      musculoskeletal change and predictors of these changes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">58</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Breast Cancer patients</arm_group_label>
    <description>A group of women with breast cancer prescribed Anastrozole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy women wit no breast Cancer</arm_group_label>
    <description>A group of healthy women wit no breast cancer prescribed Anastrozole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>Group of women with breast cancer</description>
    <arm_group_label>Breast Cancer patients</arm_group_label>
    <arm_group_label>Healthy women wit no breast Cancer</arm_group_label>
    <other_name>Anastrozole medication</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Post-menopausal Women&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group 1: Treatment Group&#xD;
&#xD;
          -  Postmenopausal breast cancer patients (stage 1 and 2)&#xD;
&#xD;
          -  Non-institutionalized&#xD;
&#xD;
          -  Prescribed Anastrozole within the preceding 1-2 weeks&#xD;
&#xD;
          -  Ambulatory&#xD;
&#xD;
          -  Ability to read and comprehend study protocol and informed consent&#xD;
&#xD;
        Group 2: Control Group&#xD;
&#xD;
          -  Healthy, age-matched postmenopausal women&#xD;
&#xD;
          -  Non-institutionalized&#xD;
&#xD;
          -  Ambulatory&#xD;
&#xD;
          -  Ability to read and comprehend study protocol and informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior Tamoxifen or Raloxifene therapy&#xD;
&#xD;
          -  Known congenital metabolic bone disease (e.g., osteogenesis imperfecta)&#xD;
&#xD;
          -  Concomitant treatment with corticosteroids&#xD;
&#xD;
          -  Patients with a history of endocrine disorders or surgical parathyroidectomy&#xD;
&#xD;
          -  Patients with disorders known to affect bone metabolism including diabetes mellitus,&#xD;
             systemic lupus erythematosus, Cushing's disease, hyperparathyroidism, chronic liver&#xD;
             disease, chronic renal failure, Paget's disease&#xD;
&#xD;
          -  Conditions preventing pQCT measurement (e.g., unable to lie flat or still for 15&#xD;
             minutes)&#xD;
&#xD;
          -  Geographically inaccessible for follow-up&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Papaioannou, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>January 10, 2007</study_first_submitted>
  <study_first_submitted_qc>January 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2007</study_first_posted>
  <last_update_submitted>September 22, 2015</last_update_submitted>
  <last_update_submitted_qc>September 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Alexandra Papaioannou</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>pQCT</keyword>
  <keyword>Anastrozole</keyword>
  <keyword>bone geometry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

